BACKGROUND: In patients with nonarteritic anterior ischemic optic neuropathy (AION) we investigated the long-term effect of hemodilution on functional results, recurrence rate in the affected and involvement of the second eye. PATIENTS AND METHODS: In a retrospective study we reviewed 24 patients ranging in age from 62 to 92 years (mean 77 years) with AION. The duration of follow-up was between 8-51 months (mean 24.8 months). All patients received iso- (Hct > 40%) or hypervolemic (Hct < or = 40%) hemodilution over 8-10 days with daily infusion of 10% hydroxyethyl-starch 200/0.5. The hematocrit decreased significant (p < 0.001) from 43.4 +/- 3.8% to 37.8 +/- 3.5% after this 10-day hemodilution treatment. RESULTS: After the longterm follow-up 29.1% of the patients had an improvement of the central vision by two or more lines, 16.7% had a deterioration, 54.2% remained unchanged. The resulting visual acuity was between 0.5-1.0 in 37.5%, between 0.4-0.1 in 41.7% and worse than 0.1 in 20.8%. Neither visual fields nor the VECP were significant changed by hemodilution. After the mean follow-up period of 24.8 months no recurrence occurred in the affected eye and the second eye as never involved. CONCLUSION: Hemodilution therapy has no significant longterm effect on visual acuity and visual fields, but it seems to have a beneficial influence on the recurrence rate in the affected and on the involvement of the second eye.
BACKGROUND: In patients with nonarteritic anterior ischemic optic neuropathy (AION) we investigated the long-term effect of hemodilution on functional results, recurrence rate in the affected and involvement of the second eye. PATIENTS AND METHODS: In a retrospective study we reviewed 24 patients ranging in age from 62 to 92 years (mean 77 years) with AION. The duration of follow-up was between 8-51 months (mean 24.8 months). All patients received iso- (Hct > 40%) or hypervolemic (Hct < or = 40%) hemodilution over 8-10 days with daily infusion of 10% hydroxyethyl-starch 200/0.5. The hematocrit decreased significant (p < 0.001) from 43.4 +/- 3.8% to 37.8 +/- 3.5% after this 10-day hemodilution treatment. RESULTS: After the longterm follow-up 29.1% of the patients had an improvement of the central vision by two or more lines, 16.7% had a deterioration, 54.2% remained unchanged. The resulting visual acuity was between 0.5-1.0 in 37.5%, between 0.4-0.1 in 41.7% and worse than 0.1 in 20.8%. Neither visual fields nor the VECP were significant changed by hemodilution. After the mean follow-up period of 24.8 months no recurrence occurred in the affected eye and the second eye as never involved. CONCLUSION: Hemodilution therapy has no significant longterm effect on visual acuity and visual fields, but it seems to have a beneficial influence on the recurrence rate in the affected and on the involvement of the second eye.
Authors: Krisztina Lantos; Zsuzsa Réka Dömötör; Nelli Farkas; Szabolcs Kiss; Zsolt Szakács; András Garami; Gábor Varga; László Lujber; Reem Kanaan; Péter Hegyi; Gergely Fehér; Valéria Gaál Journal: Int J Environ Res Public Health Date: 2022-02-26 Impact factor: 3.390